Stillger Maren Nicole, Chen Chia-Yi, Lai Zon Weng, Li Mujia, Schäfer Agnes, Pagenstecher Axel, Nimsky Christopher, Bartsch Jörg Walter, Schilling Oliver
Institute for Surgical Pathology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
Cancer Cell Int. 2023 Mar 17;23(1):49. doi: 10.1186/s12935-023-02889-8.
Glioblastoma multiforme (GBM) is characterized by an unfavorable prognosis for patients affected. During standard-of-care chemotherapy using temozolomide (TMZ), tumors acquire resistance thereby causing tumor recurrence. Thus, deciphering essential molecular pathways causing TMZ resistance are of high therapeutic relevance.
Mass spectrometry based proteomics were used to study the GBM proteome. Immunohistochemistry staining of human GBM tissue for either calpain-1 or -2 was performed to locate expression of proteases. In vitro cell based assays were used to measure cell viability and survival of primary patient-derived GBM cells and established GBM cell lines after TMZ ± calpain inhibitor administration. shRNA expression knockdowns of either calpain-1 or calpain-2 were generated to study TMZ sensitivity of the specific subunits. The Comet assay and ɣH2AX signal measurements were performed in order to assess the DNA damage amount and recognition. Finally, quantitative real-time PCR of target proteins was applied to differentiate between transcriptional and post-translational regulation.
Calcium-dependent calpain proteases, in particular calpain-2, are more abundant in glioblastoma compared to normal brain and increased in patient-matched initial and recurrent glioblastomas. On the cellular level, pharmacological calpain inhibition increased the sensitivities of primary glioblastoma cells towards TMZ. A genetic knockdown of calpain-2 in U251 cells led to increased caspase-3 cleavage and sensitivity to neocarzinostatin, which rapidly induces DNA strand breakage. We hypothesize that calpain-2 causes desensitization of tumor cells against TMZ by preventing strong DNA damage and subsequent apoptosis via post-translational TP53 inhibition. Indeed, proteomic comparison of U251 control vs. U251 calpain-2 knockdown cells highlights perturbed levels of numerous proteins involved in DNA damage response and downstream pathways affecting TP53 and NF-κB signaling. TP53 showed increased protein abundance, but no transcriptional regulation.
TMZ-induced cell death in the presence of calpain-2 expression appears to favor DNA repair and promote cell survival. We conclude from our experiments that calpain-2 expression represents a proteomic mode that is associated with higher resistance via "priming" GBM cells to TMZ chemotherapy. Thus, calpain-2 could serve as a prognostic factor for GBM outcome.
多形性胶质母细胞瘤(GBM)患者预后不佳。在使用替莫唑胺(TMZ)进行标准护理化疗期间,肿瘤会产生耐药性,从而导致肿瘤复发。因此,破解导致TMZ耐药的关键分子途径具有很高的治疗相关性。
基于质谱的蛋白质组学用于研究GBM蛋白质组。对人GBM组织进行钙蛋白酶-1或-2的免疫组织化学染色,以定位蛋白酶的表达。在体外细胞实验中,在给予TMZ±钙蛋白酶抑制剂后,测量原发性患者来源的GBM细胞和已建立的GBM细胞系的细胞活力和存活率。通过短发夹RNA(shRNA)表达敲低钙蛋白酶-1或-2,以研究特定亚基对TMZ的敏感性。进行彗星试验和γH2AX信号测量,以评估DNA损伤量和识别情况。最后,应用靶蛋白的定量实时聚合酶链反应(qRT-PCR)来区分转录调控和翻译后调控。
与正常脑组织相比,钙依赖性钙蛋白酶,特别是钙蛋白酶-2,在胶质母细胞瘤中含量更高,并且在患者匹配的原发性和复发性胶质母细胞瘤中含量增加。在细胞水平上,药理学上抑制钙蛋白酶可增加原发性胶质母细胞瘤细胞对TMZ的敏感性。在U251细胞中基因敲低钙蛋白酶-2导致半胱天冬酶-3切割增加以及对新制癌菌素的敏感性增加,新制癌菌素可迅速诱导DNA链断裂。我们假设钙蛋白酶-2通过翻译后抑制TP53来防止强烈的DNA损伤和随后的细胞凋亡,从而导致肿瘤细胞对TMZ脱敏。实际上,U251对照细胞与U251钙蛋白酶-2敲低细胞的蛋白质组学比较突出了许多参与DNA损伤反应以及影响TP53和核因子-κB(NF-κB)信号传导的下游途径的蛋白质水平受到干扰。TP53显示蛋白质丰度增加,但无转录调控。
在存在钙蛋白酶-2表达的情况下,TMZ诱导的细胞死亡似乎有利于DNA修复并促进细胞存活。我们从实验中得出结论,钙蛋白酶-2的表达代表了一种蛋白质组学模式,通过使GBM细胞对TMZ化疗“致敏”而与更高的耐药性相关。因此,钙蛋白酶-2可作为GBM预后的一个预后因素。